AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26069175 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Long arteriotomy on LAD with complete opening of LIMA and anastomosis along LAD course
Number of subjects: 40
Study 26069175 — intervention group
Group type: COMPARATOR
Intervention: Group B - Small arteriotomy only in areas where the wall of the vessel was nearly normal with sequential (Jump) method for LIMA anastomosis
Number of subjects: 40
Study 24417987 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine 5-20 mg/d
Number of subjects: 315
Study 24417987 — intervention group
Group type: EXPERIMENTAL
Intervention: retard-released felodipine 5-10 mg/d
Number of subjects: 315
Study 24417987 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine 20 mg/d
Number of subjects: 315
Study 24417987 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine
Number of subjects: 315
Study 24417987 — intervention group
Group type: EXPERIMENTAL
Intervention: retard-released felodipine
Number of subjects: 315
Study 21440891 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE or SORRY? programme
Number of subjects: 0
Study 19487960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (carboplatin and paclitaxel)
Number of subjects: 391
Study 19487960 — intervention group
Group type: COMPARATOR
Intervention: Single-agent therapy (gemcitabine or vinorelbine)
Number of subjects: 391
Study 17302059 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutem clamp fixation (PCCF)
Number of subjects: 200
Study 17302059 — intervention group
Group type: COMPARATOR
Intervention: Unilateral multifunctional external fixator (UMFEF)
Number of subjects: 200
Study 15142327 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosage group (18 daily sessions)
Number of subjects: 0
Study 15142327 — intervention group
Group type: COMPARATOR
Intervention: Lower dosage group (9 daily sessions)
Number of subjects: 0
Study 11298843 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 IU hCG
Number of subjects: 10
Study 11298843 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 IU recombinant FSH
Number of subjects: 10
Study 9486672 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurandrenolide tape (4 microg/cm2) applied once daily for up to 16 hours
Number of subjects: 30
Study 9486672 — intervention group
Group type: COMPARATOR
Intervention: Diflorasone diacetate ointment (0.05%) applied twice daily
Number of subjects: 30
Study 7799597 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermovision examination in injured persons
Number of subjects: 40
Study 7799597 — intervention group
Group type: EXPERIMENTAL
Intervention: Autodermoplasty
Number of subjects: 40
Study 7799597 — intervention group
Group type: COMPARATOR
Intervention: Thermovision examination in control group
Number of subjects: 40
Study 3059900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton bract extract (CBE)
Number of subjects: 13
Study 3059900 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 13
Study 683658 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine exteriorization (eventrated group)
Number of subjects: 386
Study 683658 — intervention group
Group type: COMPARATOR
Intervention: Uterine in situ (noneventrated group)
Number of subjects: 386
Study 683658 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 386
Study 30476517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (anti-VEGF treatment)
Number of subjects: 474
Study 28399118 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 19
Study 25767124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (8-week Skype delivered)
Number of subjects: 40
Study 25767124 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 40
Study 23773361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain that interfered at least moderately with daily living
Number of subjects: 699
Study 22716281 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol intake
Number of subjects: 1631
Study 22716281 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver as a source of retinol intake
Number of subjects: 1631
Study 22716281 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenes, vitamin C, and vitamin E intake
Number of subjects: 1631
Study 19616856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (10 weeks, twice weekly)
Number of subjects: 16
Study 19616856 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 16
Study 17095635 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 34
Study 17095635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (EX)
Number of subjects: 34
Study 16298650 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DAC) induction
Number of subjects: 298
Study 16298650 — intervention group
Group type: COMPARATOR
Intervention: No antibody induction (Control)
Number of subjects: 298
Study 12548358 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 20
Study 12548358 — intervention group
Group type: COMPARATOR
Intervention: clozapine
Number of subjects: 20
Study 9662468 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin concentrates
Number of subjects: 0
Study 7658948 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions at 90% of maximal concentric power
Number of subjects: 20
Study 7658948 — intervention group
Group type: COMPARATOR
Intervention: Eccentric contractions at 90% of maximal concentric power
Number of subjects: 20
Study 2527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg once daily)
Number of subjects: 19
Study 2527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg once daily)
Number of subjects: 19
Study 2527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and propranolol
Number of subjects: 19
Study 2527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg day‐1)
Number of subjects: 19
Study 2527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg day‐1)
Number of subjects: 19
Study 2527545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 853054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic reconstructions with lumbar sympathectomy
Number of subjects: 80
Study 853054 — intervention group
Group type: COMPARATOR
Intervention: Aortic reconstructions without lumbar sympathectomy
Number of subjects: 80
Study 853054 — intervention group
Group type: COMPARATOR
Intervention: Femoropopliteal bypass
Number of subjects: 80
Study 31104905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 278
Study 31104905 — intervention group
Group type: COMPARATOR
Intervention: Standard Radiation Therapy (RT)
Number of subjects: 278
Study 31104905 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC bowel domain
Number of subjects: 278
Study 31104905 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐CTCAE
Number of subjects: 278
Study 31104905 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT
Number of subjects: 278
Study 28596511 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg orally one hour before the operation (G1, G3)
Number of subjects: 82
Study 28596511 — intervention group
Group type: COMPARATOR
Intervention: Control groups (G2, G4)
Number of subjects: 82
Study 26073770 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-assisted calprotectin-based treatment algorithm (IBD-live)
Number of subjects: 180
Study 26073770 — intervention group
Group type: COMPARATOR
Intervention: Usual practices
Number of subjects: 180
Study 23842118 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time manikin compression feedback during simulation
Number of subjects: 30
Study 23842118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no real-time feedback)
Number of subjects: 30
Study 21899207 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Metacard MR)
Number of subjects: 24
Study 21899207 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 24
Study 19543683 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy with Toupet partial fundoplication
Number of subjects: 26
Study 16677640 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day
Number of subjects: 93
Study 16677640 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg/day
Number of subjects: 93
Study 15162251 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement of 47 mg per day
Number of subjects: 42
Study 15162251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary plan rich in iron providing 26 mg per day
Number of subjects: 42
Study 15162251 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (control group)
Number of subjects: 42
Study 10931747 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH for reconstitution (24 IU or 8 mg)
Number of subjects: 0
Study 10931747 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of rhGH (5, 10 or 15 mg per 1.5 ml)
Number of subjects: 0
Study 9308928 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole combined with radiotherapy (2 g/m2, three times weekly for 17 doses)
Number of subjects: 374
Study 9308928 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy alone (66 Gy in 33 fractions to 74 Gy in 37 fractions, 5 fractions per week)
Number of subjects: 374
Study 9308928 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole combined with radiotherapy
Number of subjects: 374
Study 9308928 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy alone
Number of subjects: 374
Study 8340985 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic cream, eutectic mixture of local anesthetics (EMLA)
Number of subjects: 27
Study 8340985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3451218 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate
Number of subjects: 0
Study 3451218 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 3451218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29447784 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 1006
Study 29447784 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (admission to intensive care and angiography after 3 days unless signs of acute ischemia or hemodynamic instability)
Number of subjects: 1006
Study 26812786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (tapered over 14 days)
Number of subjects: 42
Study 26812786 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic methylprednisolone (40 mg/mL, injected twice a week for 2 weeks)
Number of subjects: 42
Study 24988909 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenges (n=101)
Number of subjects: 198
Study 24988909 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (n=97)
Number of subjects: 198
Study 22987687 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloride channel mutations
Number of subjects: 91
Study 22987687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium channel mutations
Number of subjects: 91
Study 22987687 — intervention group
Group type: EXPERIMENTAL
Intervention: DM2 mutations
Number of subjects: 91
Study 22987687 — intervention group
Group type: COMPARATOR
Intervention: Historical normal controls
Number of subjects: 91
Study 20360917 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% of 1RM
Number of subjects: 20
Study 20360917 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 40% of 1RM
Number of subjects: 20
Study 20360917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest periods during 40% of 1RM
Number of subjects: 20
Study 20360917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest periods during 80% of 1RM
Number of subjects: 20
Study 18822733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate hydrogel (1 mL/cm2)
Number of subjects: 60
Study 18822733 — intervention group
Group type: COMPARATOR
Intervention: Saline gauze (control)
Number of subjects: 60
Study 18822733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate hydrogel
Number of subjects: 60
Study 15725048 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 322
Study 15725048 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 322
Study 12119598 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC)
Number of subjects: 34
Study 12119598 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 10461807 — intervention group
Group type: EXPERIMENTAL
Intervention: Active avoidance and behavioral control during threat/performance trials
Number of subjects: 0
Study 10461807 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control over an aversive event (loud noise)
Number of subjects: 0
Study 10461807 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral control
Number of subjects: 0
Study 7757984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (cisplatin 80 mg/m2 i.v. on day 1, vindesine 3 mg/m2 i.v. on days 1 and 8, with or without mitomycin 8 mg/m2 i.v. on day 1)
Number of subjects: 21
Study 7757984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 21
Study 2405239 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led programme
Number of subjects: 0
Study 2405239 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led programme
Number of subjects: 0
Study 2405239 — intervention group
Group type: COMPARATOR
Intervention: Perceived influence of advertising
Number of subjects: 0
Study 7216093 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release iron preparations
Number of subjects: 0
Study 7216093 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick release iron preparations
Number of subjects: 0
Study 7216093 — intervention group
Group type: EXPERIMENTAL
Intervention: All oral iron preparations
Number of subjects: 0
Study 31586587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein at 0.01% (w/v)
Number of subjects: 60
Study 31586587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein at 0.05% (w/v)
Number of subjects: 60
Study 31586587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalein at 0.1% (w/v)
Number of subjects: 60
Study 31586587 — intervention group
Group type: COMPARATOR
Intervention: Control (0% baicalein)
Number of subjects: 60
Study 28800972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 24
Study 28800972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24347521 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based program with e-mail support from an urotherapist (n=124)
Number of subjects: 250
Study 24347521 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 250
Study 24347521 — intervention group
Group type: COMPARATOR
Intervention: Postal program (n=126)
Number of subjects: 250
Study 23635552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg orally daily and rapamycin 2 mg orally daily (4 weeks on, 2 weeks off)
Number of subjects: 19
Study 21552662 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency neuromuscular electrical stimulation
Number of subjects: 30
Study 21552662 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 19146684 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH + BSO)
Number of subjects: 275
Study 19146684 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH + BSO)
Number of subjects: 275
Study 15990827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) at a loading dose of 70 mg/kg 2 hours before and 35 mg/kg at 4-hour intervals for a total of 24 hours after the procedure
Number of subjects: 256
Study 15990827 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 256
Study 15990827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC)
Number of subjects: 256
Study 12566660 — intervention group
Group type: EXPERIMENTAL
Intervention: K/DOQI recommended targets for adequacy of dialysis (weekly Kt/V 2 + creatinine clearance 50‐60 l/1.73 m(2))
Number of subjects: 0
Study 12566660 — intervention group
Group type: COMPARATOR
Intervention: Higher than recommended small solute clearance targets
Number of subjects: 0
Study 10628101 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention for preventive health care
Number of subjects: 0
Study 10628101 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 0
Study 10628101 — intervention group
Group type: COMPARATOR
Intervention: Randomized trial
Number of subjects: 0
Study 8931970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg
Number of subjects: 83
Study 8931970 — intervention group
Group type: COMPARATOR
Intervention: Intravenous indomethacin 50 mg
Number of subjects: 83
Study 1868973 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole, administered intravenously 4 times a day
Number of subjects: 9
Study 1868973 — intervention group
Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 9
Study 6354530 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 9
Study 6354530 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg) + Naloxone (0.2 mg/kg i.v.)
Number of subjects: 9
Study 6354530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30560316 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLTS (20 Hz, 1 mA below discomfort threshold)
Number of subjects: 24
Study 30560316 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLTS
Number of subjects: 24
Study 30560316 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 28893244 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once weekly (q.w.)
Number of subjects: 4202
Study 28893244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4202
Study 26802156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cediranib 30 mg once daily and saracatinib 175 mg once daily (CS)
Number of subjects: 138
Study 26802156 — intervention group
Group type: COMPARATOR
Intervention: Cediranib 45 mg once daily and placebo (C)
Number of subjects: 138
Study 25095833 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfl Protect Bond (self‐etch containing fluoride and MDPB adhesive, CB)
Number of subjects: 10
Study 25095833 — intervention group
Group type: COMPARATOR
Intervention: All‐Bond SE(TM) (self‐etch, fluoride/MDPB free adhesive, AB)
Number of subjects: 10
Study 22334456 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib at a dose of 400 mg twice daily
Number of subjects: 80
Study 22334456 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 22334456 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 80
Study 19103363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- to mid-potency topical steroids (short-term therapy for 2-4 weeks)
Number of subjects: 0
Study 19103363 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriene (calcipotriol), pimecrolimus, or tacrolimus (long-term therapy)
Number of subjects: 0
Study 17556352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S, n = 123)
Number of subjects: 237
Study 17556352 — intervention group
Group type: COMPARATOR
Intervention: Desflurane (Group D, n = 114)
Number of subjects: 237
Study 15792196 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz magnetic field exposure (96 mT)
Number of subjects: 10
Study 15792196 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemia
Number of subjects: 10
Study 15792196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (10 deep breaths)
Number of subjects: 10
Study 11965415 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinsonian patients (P)
Number of subjects: 40
Study 11965415 — intervention group
Group type: COMPARATOR
Intervention: Non-parkinsonian patients (NP)
Number of subjects: 40
Study 9798025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day for 14 days)
Number of subjects: 376
Study 9798025 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice a day for 14 days)
Number of subjects: 376
Study 9798025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 376
Study 9798025 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 376
Study 7697951 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 (250 mg)
Number of subjects: 16
Study 7697951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2507831 — intervention group
Group type: EXPERIMENTAL
Intervention: Special precautions (topical lidocaine by inhalation, bronchoscope through endotracheal tube)
Number of subjects: 20
Study 2507831 — intervention group
Group type: COMPARATOR
Intervention: Routine BAL procedure
Number of subjects: 20
Study 322635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (mean 0.91 mEq/liter)
Number of subjects: 23
Study 322635 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (1.32 ml/kg of body weight)
Number of subjects: 23
Study 322635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 23
Study 30704524 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN-low and reduced expression of hsa-miR-4324, hsa-miR-125b, hsa-miR-381, hsa-miR-145, and has-miR136
Number of subjects: 0
Study 30704524 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN-low/miR-low subgroup
Number of subjects: 0
Study 30704524 — intervention group
Group type: COMPARATOR
Intervention: Connectivity mapping
Number of subjects: 0